Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Non-Current Deffered Revenue (2022 - 2024)

Atara Biotherapeutics (ATRA) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $470000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Non-Current Deffered Revenue fell 99.36% year-over-year to $470000.0, compared with a TTM value of $470000.0 through Sep 2024, down 99.36%, and an annual FY2023 reading of $37.6 million, down 51.22% over the prior year.
  • Non-Current Deffered Revenue was $470000.0 for Q3 2024 at Atara Biotherapeutics, down from $567000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $78.0 million in Q1 2023 and bottomed at $470000.0 in Q3 2024.
  • Average Non-Current Deffered Revenue over 3 years is $43.1 million, with a median of $43.3 million recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 74.62% in 2023, then tumbled 99.36% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $77.0 million in 2022, then tumbled by 51.22% to $37.6 million in 2023, then tumbled by 98.75% to $470000.0 in 2024.
  • Business Quant data shows Non-Current Deffered Revenue for ATRA at $470000.0 in Q3 2024, $567000.0 in Q2 2024, and $719000.0 in Q1 2024.